| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.36.12.2686 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC245529 |
| https://europepmc.org/articles/PMC245529?pdf=render | ||
| P932 | PMC publication ID | 245529 |
| P698 | PubMed publication ID | 1336341 |
| P2093 | author name string | M. Davis | |
| D. C. Liotta | |||
| D. J. Nelson | |||
| J. A. Fyfe | |||
| L. J. Wilson | |||
| P. A. Furman | |||
| L. W. Frick | |||
| J. A. Wurster | |||
| M. Paff | |||
| R. E. Dornsife | |||
| P2860 | cites work | Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis | Q72717593 |
| Modified reagents for determination of urea and ammonia | Q79364911 | ||
| The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro | Q28319933 | ||
| Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues | Q28321734 | ||
| Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells | Q28323830 | ||
| Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine | Q28342752 | ||
| Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase | Q28622834 | ||
| Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine | Q34317365 | ||
| Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection | Q34527992 | ||
| Common evolutionary origin of hepatitis B virus and retroviruses | Q35599858 | ||
| 6 Statistical analysis of enzyme kinetic data | Q36541244 | ||
| Treatment of chronic hepatitis B with interferon: experience in western countries | Q38210605 | ||
| The molecular biology of the hepatitis B viruses | Q39511089 | ||
| In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus | Q39815058 | ||
| Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides | Q39816986 | ||
| A cell culture assay for compounds which inhibit hepatitis B virus replication | Q41693868 | ||
| Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases | Q44362982 | ||
| Pyrimidine nucleoside monophosphate kinase from rat bone marrow cells: purification to high specific activity by a two-step affinity chromatography procedure. | Q50914771 | ||
| Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity | Q67739035 | ||
| Autoradiography using storage phosphor technology | Q68523142 | ||
| Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial | Q69001112 | ||
| Interferon in chronic hepatitis B | Q69988451 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| cytosine | Q178425 | ||
| enantiomer | Q494483 | ||
| P304 | page(s) | 2686-92 | |
| P577 | publication date | 1992-12-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine | |
| P478 | volume | 36 |
| Q28379181 | (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes |
| Q73714389 | 1,2-di-O-acetyl-5-O-benzoyl-3-deoxy-L-erythro-pentofuran ose, a convenient precursor for the stereospecific synthesis of nucleoside analogues with the unnatural beta-L-configuration |
| Q28367605 | 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile |
| Q58620847 | A comparison of the enantioselectivities of human deoxycytidine kinase and human cytidine deaminase∗ |
| Q54386796 | Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units. |
| Q35185749 | Agents in clinical development for the treatment of chronic hepatitis B. |
| Q34373564 | Anti-HBV specific beta-L-2'-deoxynucleosides |
| Q28379623 | Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine |
| Q28369464 | Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro |
| Q40055204 | Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses |
| Q28345251 | Antiviral L-nucleosides specific for hepatitis B virus infection |
| Q43722748 | Antiviral activity and intracellular metabolism of bis(tButylSATE) phosphotriester of beta-L-2',3'dideoxyadenosine, a potent inhibitor of HIV and HBV replication |
| Q45788066 | Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment |
| Q33586790 | Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients |
| Q33951469 | Antiviral chemotherapy for the treatment of hepatitis B virus infections |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q33702348 | Cell-based and animal models for hepatitis B and C viruses |
| Q40341985 | Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells |
| Q28368026 | Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides |
| Q36607389 | Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo |
| Q43755969 | Clinical pharmacokinetics of lamivudine |
| Q45767325 | Colorimetric assay system for screening antiviral compounds against hepatitis B virus |
| Q40164099 | Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro |
| Q46486796 | Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans |
| Q34720217 | Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay |
| Q43850205 | Current status of anti-HBV chemotherapy |
| Q33933498 | Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics |
| Q40073982 | Development of a novel mouse model to evaluate drug candidates against hepatitis B virus |
| Q38405371 | Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC). |
| Q34363078 | Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. |
| Q41150476 | Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity |
| Q28344296 | Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks |
| Q44671618 | Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells |
| Q43892870 | Efficient synthesis of 2-deoxy-L-erythro-pentose (2-deoxy-L-ribose) from L-arabinose |
| Q35048263 | Emerging therapies of hepatitis B and C. |
| Q35810472 | Emtricitabine (FTC) for the treatment of HIV infection |
| Q36328961 | Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus |
| Q33947177 | End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. |
| Q39277056 | Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication |
| Q33751721 | Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model |
| Q28369077 | Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks |
| Q34519117 | Evolving therapies for the treatment of chronic hepatitis B virus infection |
| Q49888809 | Genetic Variation of the Kinases that Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells |
| Q43635554 | Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation |
| Q35810046 | High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay |
| Q45755649 | Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group |
| Q35122740 | In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. |
| Q39784993 | In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. |
| Q35897545 | Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro |
| Q28367580 | Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides |
| Q28378787 | Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine |
| Q39867025 | Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells |
| Q28344037 | Intracellular metabolism of beta-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activity |
| Q41887308 | L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity? |
| Q24682078 | Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids |
| Q33706739 | Lamivudine. A review of its therapeutic potential in chronic hepatitis B. |
| Q43504246 | Management of hepatitis B in China |
| Q40672674 | Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives |
| Q28379621 | Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro |
| Q44142327 | Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach |
| Q41428184 | New therapies for chronic hepatitis B. |
| Q41157490 | New treatments for chronic viral hepatitis B and C. |
| Q28369617 | Perspectives for the treatment of hepatitis B virus infections |
| Q34708001 | Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase |
| Q38511971 | Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus |
| Q28368057 | Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus |
| Q39652022 | Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus |
| Q36485086 | Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses |
| Q40835894 | Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication |
| Q33681508 | Present status of hepatoprotectants. |
| Q33947154 | Profound suppression of hepatitis B virus replication with lamivudine |
| Q33759430 | Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro |
| Q39471742 | Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. |
| Q77720266 | Recent advances in L-nucleosides: chemistry and biology |
| Q37120519 | Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondri |
| Q40866538 | Review: Present and future directions in the treatment of chronic hepatitis B infection |
| Q42588286 | Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients |
| Q39542444 | Stereochemical control of DNA biosynthesis |
| Q43672693 | Stereospecific synthesis and biological evaluations of beta-L-pentofuranonucleoside derivatives of 5-fluorouracil and 5-fluorocytosine. |
| Q28620349 | Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases |
| Q31618693 | Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues |
| Q46251518 | Synthesis and antiviral evaluation of novel 2,3-dihydroxypropyl nucleosides from 2- and 4-thiouracils |
| Q31440641 | Synthesis of 2',3'-dideoxy-3'-fluoro-L-ribonucleosides as potential antiviral agents from D-sorbitol |
| Q45413504 | Synthesis of 2-bromomethyl-3-hydroxy-2-hydroxymethyl-propyl pyrimidine and theophylline nucleosides under microwave irradiation. Evaluation of their activity against hepatitis B virus. |
| Q41092815 | Synthesis of L-ribofuranosyl C-nucleosides |
| Q40627994 | Synthesis of Some New 2-α-L-Arabinopyranosyl-1,2,4-triazines as Potential Antitumor Chemotherapeutics |
| Q41149344 | Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations |
| Q84274723 | Tautomerism in drug discovery |
| Q28368054 | The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase |
| Q33972465 | The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy? |
| Q43284339 | The history of antiretrovirals: key discoveries over the past 25 years |
| Q28350136 | The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance |
| Q43821538 | The synthesis and biological evaluation of novel bridging nucleoside analogues |
| Q39066550 | Therapy of HIV Infection: Current Approaches and Prospects |
| Q28378905 | Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 |
| Q33692618 | Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase |
| Q39779598 | Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus |
| Q40619887 | Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks |
| Q33808236 | Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine |
Search more.